Dr. Pasala leads Hackensack’s Structural Heart Disease program. As an interventional cardiologist, he repairs structures and places devices to treat structural heart disease. He expects the technology that supports his efforts to provide ease of use, improved visualization, and predictable procedure times—all so he can deliver optimal outcome, reduce complications, and maximize lab throughput.
New valve therapies and expansion of access to younger, lower risk patients drive SHD growth.
The Structural and Congenital Heart Center at Hackensack is involved in several key clinical trials that will shape the future of SHD. There is a tremendous amount of innovation in the field around new technologies anddevices, and one of the keys to successfully bringing this innovation to patients lies in equipping operators with the support they need to handle new devices and techniques safely and confidently.
Dr. Pasala says, "Imaging, like Philips is doing, is a big component of how safely operators can deploy these new technologies.”
Cardiac TrueVue Glass allows users to see complete color flow without losing anatomical context.
Results from case studies are not predictive of results in other cases. Results in other cases may vary. © 2022 Koninklijke Philips N.V. All rights are reserved.
Results from case studies are not predictive of results in other cases. Results in other cases may vary.
© 2022 Koninklijke Philips N.V. All rights are reserved.
You are about to visit a Philips global content pageContinue
Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.